CMF9

CMF9, a cyclic peptide molecule, is an inhibitor of the SMAD2-SMAD4 interaction. CMF9 effectively blocks the formation of the heterodimeric complex of SMAD2 and SMAD4 by inhibiting the phosphorylation of SMAD2. CMF9 has no effect on the phosphorylation of SMAD3 or SMAD1/5/8. CMF9 downregulates the expression of fibrotic markers α-SMA and COL1A1. CMF9 exhibits potent anti-fibrotic effects in mouse models by promoting the degradation of pathological extracellular matrix (ECM) and inhibiting inflammation. CMF9 can be used for the study of liver fibrosis[1].

12352209

TGF-beta/Smad

Stem Cell/Wnt; TGF-beta/Smad

COVID-19-immunoregulation

Inflammation/Immunology

O=C(N[C@@H](CCCNC(N)=N)C(N1[C@@H](CCC1)C(N[C@@H](C)C(N[C@@H](CO)C(N[C@H](CC2=CC=CC=C2)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@H]5CO)=O)=O)=O)=O)=O)=O)=O)=O)[C@H]([C@H](O)C)NC5=O

C53H74N14O16

1163.24

[1]Cheng W, et al. Discovery of Novel Cyclic Peptides as SMAD2-SMAD4 Interaction Inhibitors for the Treatment of Hepatic Fibrosis. J Med Chem. 2025 May 22;68 (10) :9958-9972.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11223/

Peptides

No Development Reported